精彩内容近期,山东康众宏医药的1类新药扶正通淋丸、新疆维吾尔自治区中医医院的1类新药补肾痹通丸均获批临床。米内网数据显示,2025Q1中国公立医疗机构终端中成药丸剂销售额超72亿元,其中心脑血管疾病用药占“半壁江山”,华润医药、上海和黄药业、北京同仁堂、达仁堂领跑市场。品牌TOP20中,复方丹参滴丸、麝香保心丸、速效救心丸稳守前三,16个中药独家品种霸屏(含剂型独家,下同)。9款中药丸剂新药蓄势,...
Source Link精彩内容近期,山东康众宏医药的1类新药扶正通淋丸、新疆维吾尔自治区中医医院的1类新药补肾痹通丸均获批临床。米内网数据显示,2025Q1中国公立医疗机构终端中成药丸剂销售额超72亿元,其中心脑血管疾病用药占“半壁江山”,华润医药、上海和黄药业、北京同仁堂、达仁堂领跑市场。品牌TOP20中,复方丹参滴丸、麝香保心丸、速效救心丸稳守前三,16个中药独家品种霸屏(含剂型独家,下同)。9款中药丸剂新药蓄势,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.